Supplement labeling
New York Senate bill (SB 4909) would require all dietary supplements to contain a statement in their labeling "clearly discernible to a customer" disclosing whether "the product has or has not been tested by [FDA]." The statement would accompany the FDA disclaimer regarding structure/function claims required under the Dietary Supplement Health & Education Act. The bill was introduced in the Senate April 20 and has been referred to the Committee on Consumer Protection
More from Archive
More from Pink Sheet
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
In an unusual move, Tracy Beth Høeg, a special assistant to FDA Commissioner Martin Makary, is leading the continued negotiations on Novavax’s delayed COVID-19 vaccine approval.